From the News Wire:
![Insulet Insulet](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_ta2hCdQ16jwxjNHm9h2KcsEA_4MOtLtsVfgHNrc9LgDgk8wOBdq2i67tNcwV-y7lR2pBANAp9f1okv9v35m8DpJ1vfZgrqk1YoVBbj9NCeyuIj9hjI286bNKN37NuuJjntubDsEg=s0-d)
![LifeScan LifeScan](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_u-guH5kV8OkiGnw0VfqJvU3DSgT_1RcVaKxEkEtucWo0aueL5eY-sYuSSuQq3dV87tgdo7gyOi_a7tOsbweBaE8uZE3STpNVysoGcoQQ4iApOgqr4Ru-8Oqpl71DNtre5PJBd95TUg=s0-d)
The next generation of Insulet's (NSDQ:PODD) OmniPod insulin pump, which is awaiting 510(k) clearance from the FDA, will be compatible with the LifeScan blood glucose monitoring technology made by Johnson & Johnson (NYSE:JNJ).
Johnson & Johnson's market-leading LifeScan blood glucose monitor will be incorporated intothe remote controller for Insulet's next-generation OmniPod insulin pump.
The 2 companies inked a deal for LifeScan's OneTouch technology to be incorporated into a new personal diabetes manager that patients use to control the OmniPod. Insulet's chief commercial officer, Peter Devlin, told MassDevice.com that the company is targeting a mid-2013 commercial release.
No comments :
Post a Comment